News & Events Press Releases

June 12, 2009
Elsevier and NextBio Sign Partnership to Enrich ScienceDirect Content, Accelerating Life Sciences, Health Sciences and Chemistry Research

— Improving Research Discoverability and Productivity —

AMSTERDAM—Elsevier today announced a new partnership agreement with NextBio, provider of an innovative platform that enables life science researchers to search, discover, and share knowledge locked within public and proprietary data to enrich ScienceDirect content. This agreement allows for an integration of NextBio's unique set of ontology-based semantic tools and a compilation of high quality sources of public data on ScienceDirect, providing health science, life science and chemistry researchers with a dynamic platform to improve discoverability and research productivity.

While most scientific information on genes, pathways, diseases, tissues and compounds is available online, it currently resides in various, disconnected, locations. Enhancing ScienceDirect with NextBio's biomedical ontology framework enables life sciences, health sciences and chemistry researchers to analyze ScienceDirect content and search ScienceDirect peer-reviewed literature together with publicly available research data from PubMed, clinical trials, experimental data, and news articles, on one single platform. The new enhancement will become available on ScienceDirect and accessible to subscribed users in summer 2009.

"ScienceDirect plays a crucial role in researchers' workflow." explained Rafael Sidi, Vice President, Product Management, ScienceDirect. "We continuously seek new ways to help accelerate science by increasing research productivity and efficiency. Partnering with NextBio will help further this mission by allowing us to provide intelligent and insightful information and smarter content to help researchers do research better.

Researchers at Stanford Genome Technology Center use ScienceDirect to enhance and accelerate their life sciences research efforts," said Dr. Baback Gharizadeh, Research Scientist at Stanford University. "We are excited about ScienceDirect leveraging NextBio's technology to explore literature findings within the context of public experimental data and related basic and clinical research. Its unique content and the ability to test new hypotheses provide the next logical step in exploiting published studies."

"We are excited to be working with the world's largest science, technology and medical publisher," said Saeid Akhtari, Co-founder, President and Chief Executive Officer, of NextBio. "Combining the depth of our search and discovery capabilities, and our unique content with the breath of the ScienceDirect platform will create new opportunities for Life Sciences, Health Sciences and Chemistry researchers to quickly gain access to the most current and comprehensive insight in their field."

About NextBio

NextBio is the provider of an innovative platform that enables life science researchers to search, discover, and share knowledge locked within public and proprietary data. NextBio's platform seamlessly combines powerful tools with unique correlated content to transform information into knowledge, providing the foundation for new scientific discoveries. NextBio helps organizations increase productivity and dramatically improve collaboration across therapeutic groups and geographic boundaries. NextBio is delivered as a SaaS (Software as a Service) solution resulting in quick deployment and rapid return on investment.

Today, NextBio is used by over a million researchers at the world's top commercial and academic institutions. NextBio's enterprise solution has been deployed at Burnham Institute for Medical Research, Celgene, Eli Lilly, Genzyme, Johnson & Johnson, Merck, Regeneron, Scripps Research Institute, Stanford University, and Takeda, among many others. To learn more about NextBio, please visit http://www.nextbio.com.

About ScienceDirect

Over a quarter of the world's full text scientific, technical and medical (STM) peer-reviewed articles - managed by renowned editors, written by respected authors and read by researchers from around the globe - are available in one place: ScienceDirect.

Elsevier's extensive and unique full-text collection covers authoritative titles from the core scientific literature including high impact factor titles such as THE LANCET, Cell and Tetrahedron. Over nine million articles are available online, including Articles in Press which offer online access to recently accepted manuscripts. The critical mass of trusted information available on ScienceDirect is unsurpassed. Coverage includes over 2,500 journals published by Elsevier and dynamic linking to journals from approximately 2,000 STM publishers through CrossRef. An expanding program of online major reference works, handbooks, book series and over 4,400 eBooks in all fields of science seamlessly interlinks with primary research referenced in journal articles.

About Elsevier

Elsevier is a world-leading publisher of scientific, technical and medical information products and services. Working in partnership with the global science and health communities, Elsevier's 7,000 employees in over 70 offices worldwide publish more than 2,000 journals and 1,900 new books per year, in addition to offering a suite of innovative electronic products, such as ScienceDirect (/http://www.sciencedirect.com/), MD Consult (http://www.mdconsult.com/), Scopus (/http://www.info.scopus.com/), bibliographic databases, and online reference works.

Elsevier (http://www.elsevier.com/) is a global business headquartered in Amsterdam, The Netherlands and has offices worldwide. Elsevier is part of Reed Elsevier Group plc (http://www.reedelsevier.com/), a world-leading publisher and information provider. Operating in the science and medical, legal, education and business-to-business sectors, Reed Elsevier provides high-quality and flexible information solutions to users, with increasing emphasis on the Internet as a means of delivery. Reed Elsevier's ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).

May 13, 2009
NextBio Appoints Jim Merryweather Vice President of Business Development

CUPERTINO, Calif.—NextBio, provider of an innovative platform that enables life science researchers to search, discover, and share knowledge locked within public and proprietary data, today announced the appointment of Jim Merryweather, Ph.D., as Vice President of Business Development. Dr. Merryweather was most recently Vice President, Strategic Planning and Business Development at Applied Biosystems.

"We are very pleased to welcome Jim Merryweather to the NextBio executive team where he will lead the company's business development strategies and initiatives," said Saeid Akhtari, NextBio's Co-founder, President and Chief Executive Officer. "His extensive industry background and relationships will be extremely valuable as NextBio pursues new strategic relationships with complementary technology partners/providers, industry organizations and consortiums, academia, and commercial clients."

"NextBio has been building significant momentum over the past several years on a base of extremely satisfied customers," said Jim Merryweather, Vice President of Business Development, NextBio. "I am very excited to be on the team and I look forward to leading the company's business development initiatives, and in turn, driving growth within our markets."

At Applied Biosystems, Dr. Merryweather was responsible for developing and implementing the AB strategic planning and business development activities, partnering with and supporting the company's four divisions to facilitate their efforts for growth in their specific businesses. Prior to that, Dr. Merryweather was the Executive Vice President, Sales & Marketing, and Executive Vice President of Pharmaceutical Corporate Development at Ciphergen Biosystems. Prior to Ciphergen, Dr. Merryweather held several positions at Incyte including Executive Vice President, Business Development & Commercial Operations; Executive Vice President, Business Development; and Senior Vice President, Client Business Management. Dr. Merryweather has also managed a variety of corporate functions at Millennium Pharmaceuticals, Inc. and Chiron, including Business Development, Corporate Development, Sales and Marketing, Research, Project Management, and Regulatory Affairs. Dr. Merryweather obtained his BS in Chemistry from Northern Illinois University and PhD in Biochemistry from Washington State University.

April 28, 2009
NextBio Enhances its Life Sciences Discovery Platform with New Tools and Features, More Intuitive Interface

Users Provided with an Integrated and Comprehensive View Across Experimental Data and Literature

CUPERTINO, Calif.—NextBio, provider of an innovative platform that enables life science researchers to search, discover, and share knowledge locked within public and proprietary data, today released an enhanced version of the company's knowledge discovery platform and products. The NextBio platform is designed to accelerate scientific discoveries and meet the research needs of individual scientists as well as pharmaceutical and biotechnology companies and research institutions seeking to apply NextBio's capabilities on an enterprise-wide basis.

"We've responded to our users' feedback with a number of enhancements to NextBio, including a new more intuitive user interface, new knowledge discovery and presentation capabilities, and improved community and personalization features," said Ilya Kupershmidt, NextBio Vice President of Products. "Together, these upgrades to the NextBio platform deliver new levels of ease in searching the vast amounts of public and proprietary data, making new discoveries, and sharing that knowledge with one's collaborators and peers."

He noted that included in the new release of NextBio is a novel "recommendation" engine that leverages NextBio's unique ontologies to recommend studies, literature, clinical trials, and news items to the researcher based on their interests.

"Researchers at The Scripps Research Institute have leveraged NextBio to support and enhance our biomedical research efforts," said Dr. Jeanne Loring, Professor of Developmental Neurobiology and Director of the Center for Regenerative Medicine. "We are very excited about the new NextBio release, which promises to provide more functionality and improve internal and external knowledge sharing."

NextBio is now offered in three product versions, each leveraging the NextBio Platform and designed to meet the specific needs of individual scientists or research groups:

• NextBio Basic — a free, publicly available web application that allows the researcher to explore the power of NextBio. NextBio Basic provides access to a curated, correlated database of public data, as well as integrated literature, published clinical trials data, scientific news, and community features.
• NextBio Professional — designed for the individual researcher or groups of researchers to effectively exploit publicly available and internally generated experimental data to enable and accelerate new scientific discoveries. NextBio Professional lets researchers make real-time discoveries of correlations between genes, pathways, diseases and compounds from a curated repository of experimental data, clinical trials data and literature.
• NextBio Enterprise — a completely integrated enterprise version designed for pharmaceutical and biotechnology companies, commercial and non-profit R&D organizations, and academic institutions. NextBio Enterprise combines the features available in NextBio Professional with state-of-the-art security and data protection and an extensive set of APIs, allowing seamless integration into other research systems, workflows and processes.

The NextBio Platform is a robust, fault tolerant, secure and configurable infrastructure that is designed to support an individual researcher or an organization with tens of thousands of employees in locations around the world. The NextBio Platform provides a unique ontology-based semantic framework that connects highly heterogeneous data and textual information.

"The pace of life sciences research is accelerating, with enormous amounts of data being generated each year," commented Mr. Kupershmidt. "Whether you are an individual scientist or a member of a major company or institution's R&D efforts, NextBio's research platform, unique content and products provide an unparalleled way to quickly transform data into new scientific knowledge."

April 27, 2009
NextBio Announces Licensing Agreement with Merck & Co., Inc.

CUPERTINO, Calif.—NextBio, provider of an innovative platform that enables life science researchers to search, discover, and share knowledge locked within public and proprietary data, today announced a licensing agreement with Merck & Co., Inc. NextBio offers the life sciences enterprise secure data access, knowledge discovery and collaboration tools, and enterprise integration capabilities for seamless correlation of internal research data.

"We are pleased Merck has chosen NextBio as a drug discovery and development partner," said Saeid Akhtari, Co-Founder and Chief Executive Officer of NextBio. "Merck's adoption of the NextBio solution validates our unique approach to solving the information bottleneck currently impacting research-driven pharmaceutical and biotechnology companies worldwide. We look forward to further building and extending our relationship with Merck's researchers over the coming years."

April 14, 2009
NextBio Receives Phase II SBIR Grant to Add New Genomic and Proteomic Content

CUPERTINO, Calif.—NextBio, provider of an innovative platform that enables life science researchers to search, discover, and share knowledge locked within public and proprietary data, today announced the receipt of a Small Business Innovation Research (SBIR) grant from the U.S. National Institutes of Health (NIH). The grant will provide approximately $1,000,000 over two years to support the incorporation of genomic and proteomic information from additional vertebrate organisms into NextBio. It will also help fund NextBio's development of infrastructure to support plant research by incorporating Arabidopsis, corn, rice and soy plant genomics into its cross-species knowledge discovery framework.

"Life science researchers use critical biological information from studies of diverse species to make key correlations that help them discover new knowledge about human or plant physiology and disease," said Saeid Akhtari, NextBio President and Chief Executive Officer. "With this support from NIH, we will extend the NextBio offering enabling researchers to leverage a wider range of data from model organisms to better understand biology."

As part of this effort, NextBio will develop ontologies, translational methodology and cross-study comparison logic to connect findings across different organisms. Furthermore, the company will develop advanced statistical and visualization methods to help correlate and interpret the data. The new species information will build upon a wealth of information already supported within NextBio from human, mouse, rat, fly, worm and yeast systems.

April 7, 2009
NextBio Announces First Three Recipients of Student Travel Grants

— Winning Essays Convey How NextBio Helped Them Find Correlations, Make Discoveries Between their Research and Published Data —

CUPERTINO, Calif.—NextBio, provider of an innovative platform that enables life science researchers to search, discover, and share knowledge locked within public and proprietary data, today announced the inaugural recipients of the company's NextBio Travel Grant. Each of the winners will receive $500 to support their travel to scientific conferences. The NextBio Travel Grant program was designed to encourage and support graduate student attendance at conferences, where they are exposed to new ideas, research strategies and potential collaborators just as NextBio itself supports knowledge discovery and collaboration.

"We are very pleased to make the first three awards in this ongoing grant program," said Saeid Akhtari, NextBio President and Chief Executive Officer. "Our judges were very impressed with the quality of the entries and how clearly they articulated the value that NextBio delivers in its ability to rapidly uncover knowledge buried in the enormous wealth of publicly available and proprietary data."

The first three NextBio Travel Grant recipients are:

• Bryan Dickinson, graduate student in chemistry at the University of California Berkeley, Berkeley California USA
• Laura Mariani, graduate student in neuroscience at Emory University, Atlanta Georgia USA; and
• Khader Shameer, senior research fellow in computational biology at the National Centre for Biological Sciences, Bangalore India

To read the winning essays, find out more about the winners, and learn more about the NextBio Travel Grant program, please visit: http://www.nextbio.com/b/corp/grants.nb

February 24, 2009
Novel Search Strategies to be Presented by NextBio at the Molecular Medicine Tri-Conference

— Best Practices for Maximizing Life Science Research Productivity Will be Offered at San Francisco Meeting —

CUPERTINO, Calif.—Life science research organizations can maximize the productivity and return on investment (ROI) of their research through the use of new search strategies capable of correlating internal research findings with data from the world's publicly available large-scale studies, says Ilya Kupershmidt, co-founder of NextBio, provider of the leading life sciences search engine. On February 27, 2009, at the upcoming Molecular Medicine Tri-Conference in San Francisco, California, Mr. Kupershmidt, Vice President of Products at NextBio, will present best practices related to accessing, understanding and finding new discoveries within the world's publicly available life sciences data and literature.

"New search solutions like NextBio enable scientists to quickly search and find correlations between their own work and the vast amount of research data that has been created and published worldwide. Leveraging this knowledge empowers organizations to make important discoveries more quickly than ever before, greatly increasing the productivity of their research efforts and opening new doors to global collaboration and knowledge sharing," said Mr. Kupershmidt.

Mr. Kupershmidt's presentation will take place on February 27 at 10:05 am PST at the Molecular Medicine Tri-Conference, which is being held from February 25-27 at San Francisco's Moscone North Convention Center.

January 20, 2009
NextBio Appoints Andrew Grygiel as Vice President of Marketing

CUPERTINO, Calif.—NextBio, provider of the leading life sciences search engine, today announced the appointment of Andrew Grygiel as Vice President of Marketing. In this role, Mr. Grygiel will lead the company's overall global marketing efforts, including branding, positioning, public relations and product marketing.

"Andrew is an outstanding marketing professional and we're very excited to welcome him to the management team at NextBio," said Saeid Akhtari, Chief Executive Officer of NextBio. "Andrew's track record with high growth technology companies — from cutting-edge Silicon Valley start-ups to successful life science category leaders &mdash is unmatched. We expect his leadership to create world-class marketing programs that drive additional growth for NextBio."

Mr. Grygiel comes to NextBio with more than 20 years of domestic and international high technology marketing experience. Mr. Grygiel has spent much of his career bringing information technology solutions to the life sciences marketplace. Prior to joining the company he served as Senior Vice President of Global Marketing at Orchestria, where he helped establish the company as a leader in information protection and control. Before Orchestria, he served as Vice President of Global Industries for EMC's multi-billion dollar information and content management software group. During Mr. Grygiel's tenure at EMC, he was responsible for all aspects of industry marketing and development, which contributed to the company's 20 percent plus year-over-year license revenue growth and EMC's Software Group being recognized as the 7th largest software company in the world.

Prior to EMC, Mr. Grygiel was Vice President of Life Sciences at Documentum, where he played an instrumental role in significantly growing the life sciences business and customer base, making Documentum the leader and de-facto standard in life sciences content management and collaboration. EMC purchased Documentum in a transaction valued at approximately $1.7 billion. Mr. Grygiel also held senior management roles at InnaPhase, Hewlett-Packard, and Perkin-Elmer.

January 13, 2009
NextBio Appoints Sergio Gurrieri as Senior Director of Business Development

CUPERTINO, Calif.—NextBio, provider of the leading life sciences search engine, today announced the appointment of Sergio Gurrieri, Ph.D., as Senior Director of Business Development. In this role, Dr. Gurrieri will be responsible for identifying new growth opportunities and strategic business development initiatives.

Dr. Gurrieri joins NextBio with 20 years of experience in life sciences research, marketing and business development. Dr. Gurrieri has extensive expertise in the identification, establishment and management of partnerships, sponsorships, and licensing opportunities. Prior to joining NextBio, he served as Group Marketing Manager at Millipore Corporation, where he led the development and execution of Millipore's global eBusiness strategies covering a portfolio of 25,000 products.

Prior to Millipore, Dr. Gurrieri held a number of research and development, business development and marketing roles at Invitrogen and BD Biosciences Clontech. Dr. Gurrieri has authored 26 research articles and reviews in top-rated international scientific journals. Dr. Gurrieri holds an MBA in Management and Marketing from San Diego State University, and an MS and PhD in Biophysical Chemistry from the University of Oregon.

"I am very pleased to welcome Sergio to NextBio," said Saeid Akhtari, Chief Executive Officer of NextBio. "Sergio's rich experience in driving strategic development initiatives for life science companies is an ideal fit for NextBio as we continue to identify and capitalize on the tremendous market opportunities available to us. We are confident Sergio's leadership will enrich our ability to deliver increasing value to our customers and partners."

October 2, 2008
NextBio Crosses Threshold to Fastest Growing Life Science Search Engine on the Web

— NextBio Used by Over 300,000 Researchers Since Public Launch —

Cupertino, CA, October 2, 2008 - NextBio, a life science search engine that empowers researchers and clinicians to search and correlate public scientific data and literature, share their own research findings and collaborate with colleagues, today announced that over 150,000 unique monthly visitors used its website in September 2008. Since the launch of its publicly available search engine earlier this year, NextBio has served over 300,000 researchers and clinicians spanning over 200 countries. In addition to the free public version of the NextBio search engine, NextBio offers a powerful enterprise solution with a suite of exclusive features for pharmaceutical and biotechnology companies and major academic and governmental research institutions.

"NextBio was extremely helpful when it came time to interpret and publish our research findings," stated Huichun Xu, MD, at the MIND Institute and Department of Neurology at the University of California at Davis. "We uploaded results that our lab generated while studying different types of stroke. In a matter of minutes, literally, we were comparing our data to gene signatures from thousands of other experiments, collected from many data sources. The sheer content available at your fingertips is amazing. Searching for this information without NextBio would have been a huge project in and of itself."

"Researchers at the Burnham Institute for Medical Research have been using NextBio for over a year to better understand and combine public life sciences research with our internal data," stated Alexey Eroshkin, Ph.D., from the Burnham Institute for Medical Research. "During this time, the number of NextBio users at Burnham has nearly doubled, and that number continues to grow. We are enthusiastic about the upcoming product releases."

"We have seen an explosion in the traffic on our public search engine," said Saeid Akhtari, co-founder and CEO of NextBio. "While we continue to see strong traction among our paying pharmaceutical, academic and biotech customers for the enterprise version of our product, which includes advanced security and analytical features, the viral growth of our public site has exceeded all expectations. We are gratified that scientists all across the world are using NextBio to make new breakthrough discoveries."

As NextBio continues to innovate its search engine, add new enterprise features and enhance its free community and collaboration offerings, its popularity has grown to make it the number one destination for the life sciences community for search and collaboration.

June 24, 2008
NextBio Awarded the 2008 Frost & Sullivan North American Life Sciences "Customer Value Enhancement Award" for Innovative Life Science Search Engine

— NextBio Positioned to Drive the Industry Towards More Open and Collaborative Approach to Research —

Cupertino, CA, June 24, 2008 - NextBio, the developer of an interactive life science search engine, announced today that it has been awarded the prestigious 2008 Frost & Sullivan North American Life Sciences Customer Value Enhancement Award.

NextBio's unique life science tool empowers researchers and clinicians to search publicly available data, openly share their own research findings and collaborate as never before. "By encouraging 'open biology', this tool aims to shift the mentality of a community accustomed to guarding its data," explains Frost & Sullivan analyst Christi Bird. "Ultimately, NextBio is positioned to drive the industry towards a more open and collaborative approach to scientific research." NextBio's powerful data and literature search engine is used every day by top pharmaceutical companies and tens of thousands of researchers and clinicians worldwide.

In recognizing NextBio for this Award, Frost & Sullivan highlighted the company's commitment to providing a user-friendly, fast and thought-provoking tool for its customers. "NextBio has transformed the way its end-users approach research," explains analyst Christi Bird. "NextBio's customers rave that what was once a tedious task, now takes only minutes." NextBio empowers scientists to easily find correlations in the scientific data and to discover powerful connections and inferences between the publicly available data and their own proprietary experimental results. The Frost & Sullivan research notes that NextBio encourages the generation of unique hypotheses, as researchers can now examine interactions between seemingly disparate species and platforms by using the search engine.

Frost & Sullivan analyst Christi Bird concluded, "With a growth strategy that benefits its customers' research and a strong commitment to driving the industry towards open biology, NextBio is uniquely positioned to accelerate scientific discovery."

"We are very pleased to receive this Award in recognition of our efforts to make NextBio an essential resource for life science research and collaboration among scientists and clinicians worldwide," said Saeid Akhtari, co-founder and Chief Executive Officer of NextBio. He noted that the company had recently made a free version of the NextBio life science search engine available to the general public at http://www.nextbio.com.

The Award is part of Frost & Sullivan's Best Practices Awards program to recognize companies in a variety of regional and global markets for demonstrating outstanding achievement and superior performance in areas such as leadership, technological innovation, customer service, and strategic product development. Selection is made by industry analysts who compare market participants and measure performance through in-depth interviews, analysis and extensive secondary research. For more on the award and NextBio's selection please see http://www.frost.com/prod/servlet/meawards-hall-of-fame-feature.pag?sid=134767799

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, partners with clients to accelerate their growth. The company's TEAM Research, Growth Consulting and Growth Team Membership empower clients to create a growth-focused culture that generates, evaluates and implements effective growth strategies. Frost & Sullivan employs over 45 years of experience in partnering with Global 1000 companies, emerging businesses and the investment community from more than 30 offices on six continents. For more information about Frost & Sullivan's Growth Partnerships, visit http://www.awards.frost.com.

June 9, 2008
NextBio Life Science Search Engine Advances Systems Biology Approach to Research

— Human Disease-Associated Mutation and Mouse Knockout Data Now Part of Rich Collection of Gene Expression Studies Available for Search —

Cupertino, CA, June 9, 2008 - NextBio's life science search engine significantly advances the systems biology approach to R&D and drug discovery, says NextBio co-founder Ilya Kupershmidt, who will discuss the innovative research tool at the Beyond Genome Conference this week. He will also update the life science community on the latest additions to NextBio's content base, including new human disease mutation and mouse knockout data sets. NextBio is the leading life sciences search engine and enterprise Software-as-a-Service (SaaS) solution being used by thousands of researchers every day and the world's leading pharmaceutical and biotech companies. The Beyond Genome conference is being held in San Francisco from June 8 - 11.

"We recently reached another milestone in the development of the NextBio life science search engine by integrating human disease-associated mutation and mouse knockout data with the rich collection of gene expression studies already available to users," stated Mr. Kupershmidt, Vice President of Product Management at NextBio. "The new types of measurements add another dimension to NextBio's life science search engine by providing common human gene mutations and mouse gene knockouts associated with cancer, and neurological and metabolic disorders, amongst others."

On Tuesday, June 10 at 3:35 pm, Mr. Kupershmidt will present the latest innovations of the NextBio life science search engine, including several different search strategies of use to both commercial and academic researchers and new content. Among the new features to be presented: easily searchable clinical trial information, expanded experimental data sets, enhanced literature search, advanced query capabilities, added enterprise security and new APIs.

NextBio recently announced the public launch of the free version of its life science search engine, enabling any researcher or clinician to search the world's public life sciences data and literature. Moreover, by becoming a registered user of NextBio, researchers can import their own experimental data into the NextBio search engine, share it with the community and collaborate with others. "Our goal at NextBio is to support and advance the vision of Open Biology," said Mr. Kupershmidt, "by letting scientists around the globe easily share information and collaborate as never before."

NextBio is a sponsor and presenter at the Beyond Genome conference, and representatives from the company will be available from June 8-11 to discuss the NextBio life science search engine and its applications as an essential tool for every life sciences researcher and clinician. NextBio will also be hosting an on-line presentation of NextBio and its capabilities on Friday, June 13, at 11 am PDT. This presentation will cover applications of NextBio across diverse research settings both within academic and commercial organizations.

More information on the "Beyond Genome" conference and NextBio Webinar can be found at http://www.nextbio.com/b/corp/events.nb.

April 28, 2008
NextBio Announces Public Launch of its Life Science Search Engine

— New Paradigm for Basic and Clinical Research Promotes Open Biology —

— NextBio Search Engine to be Highlighted April 29 at Bio-IT World Conference —

Cupertino, CA, April 28, 2008 - NextBio today announced the next step in making Open Biology a reality: a free version of the NextBio life science search engine has been made available to the general public. Using NextBio, any researcher or clinician can search the world's public life sciences data and literature - over 10,000 experiments, 16 million articles, and literally billions of data points. Moreover, users can import their own experimental data into the NextBio search engine, share it with the community, and collaborate with others as never before.

"The NextBio life science search engine presents a powerful and intuitive solution available for researchers and clinicians who wish to truly unlock the value of large-scale studies in the public domain," stated Leroy Hood, M.D., Ph.D., President of the Institute for Systems Biology. "NextBio is an entirely new and better way of doing scientific research."

"With the public launch of the free version of our life science search engine, our goal is to make NextBio an invaluable resource for every researcher and clinician in the world," said Saeid Akhtari, NextBio's co-founder and Chief Executive Officer. "While we continue to grow our enterprise accounts with the world's leading R&D companies and organizations who demand added data integration services, security and support, the free version of our product is the culmination of years of development and our vision of open collaboration in science."

"The public launch of NextBio's free search and collaboration tools is at the center of our vision of Open Biology," stated Ilya Kupershmidt, co-founder and VP of Product Management at NextBio. "NextBio's search engine provides a unique opportunity for the research community to collaborate through information sharing and to perform an important part of their biological work in silico. Our users can glean new insights into gene function, disease progression and compound effects, as well as into their own studies using the world's quality public experiments done to date."

With NextBio, researchers and clinicians can:

• Search in real-time over 1,200,000,000 scientific data points, tens of thousands of study results and millions of scientific articles
• Find topics of interest quickly with an intelligent semantic auto-complete search feature
• Make correlations across six species, enabling effortless exploration of animal models relative to human studies
• Search NextBio to validate or generate novel hypotheses prior to investing in new experiments
• Understand their own study results by correlating them with the world's collective experimental data
• Create their own user profiles to more easily collaborate with scientists around the world

Videos explaining the NextBio life science search engine and how it works, as well as a demonstration of a search, are available for viewing at http://www.nextbio.com/b/corp/demo.nb.

NextBio Featured at Bio-IT World Conference

The NextBio life science search engine will be highlighted this week at the Bio-IT World Conference in Boston. In a presentation on Tuesday April 29 at 2:30 pm Eastern Time, Ilya Kupershmidt, NextBio co-founder and Vice President of Product Management, will describe the conceptual framework behind NextBio and present applications investigating diverse biological questions. More information on the conference can be found at http://www.nextbio.com/b/corp/events.nb.

February 4, 2008
NextBio Life Science Search Engine Licensed by the Burnham Institute to Speed Research Across Public and Private Data

February 4, 2008 - NextBio today announced that it has renewed and expanded its licensing agreement with the Burnham Institute for Medical Research in San Diego, California, for the use of NextBio's innovative life science search engine. Under the agreement, every scientist at the Burnham Institute will gain access to the NextBio life science search engine, enabling them to search data from both public and proprietary sources to bring their own experimental results within the context of other research findings worldwide.

"In one of our key studies, we used the NextBio search engine to interpret the gene expression changes between adenoma tumors associated with two distinct genotypes," said Robert Oshima, Ph.D., Tumor Development Program co-Director and Professor at the Burnham Institute. "Instead of manually evaluating hundreds of genes through literature, we were able to quickly search for conditions with similar biological changes using a combined collection of public studies. NextBio has proven to be valuable in interpreting gene expression changes in our experiments."

"The ability of Burnham scientists to utilize huge quantities of public and internal experimental data in an easy way is fundamental to our research efforts," commented Craig Hauser, Ph.D., Cancer Center Associate Director at Burnham Institute for Medical Research. "NextBio's life science search engine enables our researchers and clinicians to generate and validate new hypotheses using information from thousands of large-scale experimental studies."

"We are delighted to see the Burnham Institute provide access to NextBio for its entire research staff and believe that NextBio will become an integral part of their daily research," said Ilya Kupershmidt, NextBio's Vice President of Product Management. "We are very pleased that Burnham, as one of our pioneering customers, has renewed and expanded its license to use NextBio."

NextBio is a life science search engine that enables researchers and clinicians to access and understand the world's life sciences information to find important new correlations, make discoveries, and generate hypotheses as never before. NextBio is implemented as a "Software as a Service" (SaaS) model that permits users to use its search engine directly via the web and internal client sites through the NextBio Application Programming Interface (API). NextBio is used daily by some of the world's leading research enterprises, including Stanford University, UC Davis, Scripps Research Institute, Johnson & Johnson, Celgene and Genzyme.

January 28, 2008
NextBio Life Sciences Search Engine Licensed by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

— Innovative Search Engine Helps Drug Discoverers Understand Research Data in the Context of Other Findings —

January 28, 2008 - NextBio today announced that it has entered into a major licensing agreement with Johnson & Johnson Pharmaceutical Research & Development, L.L.C. for use of NextBio's innovative life sciences search engine and collaboration platform. NextBio is being used by researchers and clinicians at Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Tibotec Therapeutics and Centocor.

"This agreement is a milestone for NextBio," said Saeid Akhtari, NextBio's President and Chief Executive Officer. "Johnson & Johnson is one of the world's most successful and innovative companies. We are very pleased to be working with their outstanding team in making NextBio an integral part of their internal R&D efforts. We are seeing major validation of our Software as a Service (SaaS) model as leading enterprises securely integrate and search their internal data using our innovative search engine."

"We are seeing tremendous demand within the industry for the ability to intelligently search across vast quantities of internal and public biological and chemical data in real time — a concept pioneered by NextBio," commented Ilya Kupershmidt, NextBio's Vice President of Product Management. "Johnson & Johnson joins a growing number of premier research institutions and companies who are using NextBio daily in their research efforts, including Stanford University, UC Davis, Scripps Research Institute, Celgene and Genzyme."

NextBio is a search engine that enables researchers and clinicians to access and understand the world's life sciences information to find important new correlations, make discoveries, and generate hypotheses as never before. NextBio is implemented via a Software as a Service (SaaS) model that users can search directly or via internal company sites through the NextBio Application Programming Interface (API).

October 9, 2007
Former SVP of Roche joins NextBio's Scientific Advisory Board

Cupertino, CA, October 9, 2007 - NextBio announced today that Dr. B. Michael Silber, former Senior Vice President and Site Head of Preclinical R&D (Safety & Technical Sciences) at Roche Pharmaceuticals, has joined the company's Scientific Advisory Board.

"Dr. Silber has been a major figure in the pharmaceutical industry for more than twenty years. His leadership has been essential in the successful development of a variety of innovative new medicines that are widely used in the world today," stated NextBio co-founder and CEO Saeid Akhtari. "We are honored that Michael Silber has joined the NextBio team. His experience and commitment to scientific excellence will be vital as we move forward."

"I am delighted to join NextBio's Scientific Advisory Board," stated Dr. Silber. "They have a clear vision of how to help scientists and clinicians effectively use the vast amount of life sciences data that is now available. By putting this information at their fingertips, NextBio is enabling every scientist and clinician to greatly increase the pace of scientific discovery."

Prior to joining NextBio, Dr. Silber held senior executive positions in several of the world's leading Pharma/Biotech companies, including most recently as Senior Vice President and Site Head of Preclinical R&D (Safety & Technical Sciences) at Roche Pharmaceuticals. He has experience developing innovative new medicines in major diseases and has expertise in root cause analysis of R&D attrition/success. Dr. Silber has published over 120 research articles, book chapters, and abstracts, and is a member of the editorial boards of six journals. He has also held other key positions, including Vice President of R&D at J&J/ALZA, Director of Genomic and Proteomic Sciences at Pfizer Research, Senior Director and Division Head of Pharmacology and Toxicology at Cetus (Novartis), Director and Head of Drug Metabolism at Lederle (Wyeth), and Assistant Professor, University of Washington School of Medicine and Pharmacy. Dr. Silber has a PhD in Pharmaceutical Chemistry and Pharmacology from the University of California, San Francisco.

July 11, 2007
Search Expanded to Chemistry with Latest Version of NextBio

Cupertino, CA, July 11, 2007 - NextBio today announced that it has released a new version of its search engine for life sciences data with chemistry-enabled search features. The latest update of NextBio contains powerful search capabilities and content designed to help researchers and clinicians explore high-throughput and high-content screening data.

"We are very impressed with the richness of content and ease of use that the latest version of NextBio provides our researchers", stated Dr. Nick Tsinoremas, Senior Director of Informatics at Scripps Florida. "NextBio enables us to cover key areas of importance to Scripps - linking genomic and chemical information under a single, powerful search interface. In addition, NextBio has become our central web-based repository for internal studies, allowing real-time collaboration."

"At NextBio, we are focused on building the most versatile and user-friendly search and collaboration engine for the life sciences community," said Ilya Kupershmidt, Vice President of Product Management at NextBio. "The latest release with chemistry-enabled features is a strong testament to our commitment to systematically incorporate the world's diverse large-scale data into NextBio. This release is particularly important since it demonstrates the capabilities of NextBio's search technology beyond commonly used genomic platforms."

NextBio enables scientists, researchers and clinicians to:

• Search and correlate information across data types, domains and species
• Manage, search and correlate internal biological and chemical data
• Share data through a secure access-controlled environment
• Utilize an extensive biomedical ontology for data consistency

June 26, 2007
NextBio Announces License Agreement with Genzyme

Cupertino, CA, June 26, 2007 - NextBio today announced that it has entered into a licensing agreement with Genzyme for use of its innovative life sciences data search engine and collaboration platform.

"We were very impressed with NextBio's powerful search and data correlation features, quality and breadth of content and attention to detail in critical areas such as usability, security and scalability," said Dr. Steve Madden, Director of Functional Genomics at Genzyme. "We believe that NextBio is a valuable resource that empowers our researchers to do better science and generate more focused hypotheses."

"We are very pleased that Genzyme has chosen NextBio as a critical resource," said Saeid Akhtari, co-founder and CEO of NextBio. "Genzyme's selection of NextBio is a testament to our ability to serve vital needs of the pharmaceutical and biotechnology industries. NextBio directly addresses the urgent research and productivity demands of life scientists and researchers who need to gain a greater understanding of the biological relevance of their high-throughput data."

NextBio is a life sciences data search engine and community data sharing platform that introduces the web 2.0 paradigm of instant access, user-generated content and collaboration to life scientists and clinicians worldwide. Launched in 2006, NextBio's search engine has rapidly gained adoption among users in leading academic institutes and pharmaceutical/ biotechnology companies who have endorsed its visionary approach to data search and sharing.

June 6, 2007
NextBio Announces $7 Million Series B Financing for Life Sciences Search Engine

Cupertino, CA, June 6, 2007 - NextBio , a Cupertino-based company that has developed the first search engine for life sciences data, today announced the closing of a $7 million "Series B" financing led by Newbury Ventures (www.newburyven.com), with participation by existing investors.

The new funds will be used to further expand NextBio's industry-leading content, scale its technology infrastructure to handle millions of queries, and build its community collaboration and data sharing features. Bruce Bauer, Senior Managing Director of Newbury Ventures, will join NextBio's Board of Directors.

"We believe there is a tremendous market opportunity for a search engine that fundamentally changes the way life science researchers find and share information," stated Bruce Bauer of Newbury Ventures. "NextBio's outstanding customer traction and feedback makes this an especially exciting investment for us. We believe that NextBio has the seasoned team, technology, and long-term vision to transform an entire industry."

"We are excited to bring on board an experienced investor that shares our passion for revolutionizing life sciences research and drug development," said Saeid Akhtari, NextBio's co-founder and CEO. "We will utilize this significant capital infusion to accelerate our innovation, expand our content, and rapidly globalize adoption of the NextBio search and collaboration engine."

NextBio is a life sciences data search engine and community data sharing platform that introduces the web 2.0 paradigm of instant access, user-generated content and collaboration to life scientists and clinicians worldwide. Launched just eight months ago, NextBio's search engine has rapidly gained traction with users in over 60 academic institutes and pharmaceutical/ biotechnology companies that have endorsed its visionary approach to data search and sharing.

About NextBio

NextBio is the world's first data search and collaboration engine for life scientists and clinicians. Founded by a team of visionary innovators, NextBio addresses a fundamental need within R&D to effectively leverage vast quantities of internal and public life sciences information by connecting millions of researchers and clinicians through its search and share engine. NextBio's value in improving research efficiency and effectiveness has already been validated at the world's leading research organizations. For more information, visit www.nextbio.com.

About Newbury

Newbury Ventures is an international venture capital group focused on investing in and growing entrepreneurial companies in the technology, communications, information technology, and health care industries. Founded in 1992, Newbury is known for its insight, integrity and global approach to the business of venture capital, and has successfully managed investments of over $500 million in North America and Europe. Newbury's partners have financed well over 100 successful emerging growth technology companies, including Okena, Netro, Precise Software, Corvis/Algety, nCipher, and ACC. Newbury has offices in Redwood Shores, California; Ottawa, Canada; and Paris, France.
www.newburyven.com

March 6, 2007
Former CSO of Illumina, Dr. David Barker, Joins NextBio Board of Directors

Cupertino, CA, March 6, 2007 - NextBio today announced that Dr. David L. Barker, recently retired Chief Scientific Officer of Illumina, Inc. (NASDAQ:ILMN), has joined its Board of Directors. In his role as director, Dr. Barker will help define the strategic goals of the company. Dr. Barker is the latest addition to a team of directors and advisors that includes leaders in science and medicine such as Dr. Leroy Hood of the Institute for Systems Biology and Dr. Ron Davis of the Stanford Genome Technology Center.

"Dr. Barker's addition to our team provides tremendous validation of NextBio's paradigm of empowering life scientists and clinicians everywhere with our data search engine," said NextBio co-founder and CEO Saeid Akhtari. "We are honored and pleased that Dr. Barker shares our vision for the Company and welcome him to our Board."

"I am truly excited about NextBio and its future as a valuable resource for researchers and clinicians," stated Dr. Barker. "What NextBio has created is a remarkable search engine and content knowledgebase that seamlessly integrates heterogeneous data from all life science sources, changing the way researchers and clinicians work."

"Dr. Barker's addition to our team further reinforces our mission to advance the way life sciences research is conducted," said Dr. Mostafa Ronaghi, co-founder of NextBio.

Prior to joining NextBio, Dr. Barker was Vice President and Chief Scientific Officer at Illumina, Inc., in San Diego, California, which he joined in March 2000. Illumina is one of the leading companies in the life sciences space and an innovator in the BeadArray chips used for genotyping. From 1998 to 2000, Dr. Barker served as Vice President and Chief Science Advisor at Amersham Biosciences, now part of General Electric. From 1988 to 1998, Dr. Barker held senior positions, including Vice President of Research and Business Development, at Molecular Dynamics, Inc., until the acquisition of Molecular Dynamics by Amersham. In his academic career, Dr. Barker conducted interdisciplinary research in neurobiology as a postdoctoral fellow at Harvard Medical School, Assistant Professor at the University of Oregon and Associate Professor at Oregon State University. Dr. Barker holds a BS with honors in Chemistry from the California Institute of Technology and a PhD in Biochemistry from Brandeis University.

January 31, 2007
NextBio Adds New Security Features and Support for Additional Species

Cupertino, CA, January 31, 2007 - NextBio today announced new features and content that give researchers and clinicians the ability to explore the world's largest resource of experimental study results with more ease and security using the NextBio data search, store and share engine. Saeid Akhtari, CEO and cofounder of NextBio, announced:

"We are excited to provide our users with the opportunity to search much more data across new species as we continue to organize and make accessible a new world of life sciences information to our users. Our close relationship with our pilot customers has enabled us to respond quickly to our users' needs and requirements. The new features enable researchers and clinicians to improve productivity by having more immediate access to relevant study results using our revolutionary search engine."

The new release of NextBio provides major content updates in the areas of clinical genomics, stem cells and development, as well as compound and tissue profiling. Among the new features are an improved user interface and query capabilities and an infrastructure to securely store and manage proprietary internal data from individual users and organizations.

"Our most recent updates represent a significant milestone for NextBio and major enhancements for our users. The feedback has been tremendous, and we are working hard to continue our innovations," commented Ilya Kupershmidt, cofounder of NextBio and VP of Product Management.

Overview of NextBio Enhancements:

• User Interface (UI) Improvements
  The NextBio UI has been upgraded to give users better performance and experience when dealing with large sets of data. Additional improvements include new visualization features for queries and offering users new and powerful ways of exploring their findings.

• More Content
  NextBio now includes thousands of new study results across diverse disease areas, with an emphasis on clinical genomics, compound and tissue profiling studies, as well as stem cells and development. With this latest update, NextBio provides researchers and clinicians with the largest resource of high quality large-scale study results in the world.
• Additional Species
  NextBio now offers a fully transparent environment to explore and correlate internal and public data from human, rat, mouse, worm, fly and yeast genomes. For example, researchers can seamlessly correlate information from genetic studies in drosophila with human disease signatures, or find relationships between yeast drug targets and tissue-specific profiles in humans.
• Available as SaaS (Software as a Service)
  NextBio offers fully secure on-demand access to its software via the internet. Each customer will now access their own private account where internal data can be securely stored, managed and explored. This major development places NextBio at the cutting edge of the latest technology and minimizes maintenance and support issues for our customers. NextBio can also be deployed behind the client's firewall.

In addition, NextBio is pleased to announce a series of webcasts for customers and partners to showcase the latest features of its search engine. The initial webcast in the series "What's New in NextBio" takes place on Tuesday, February 6, 2007 at 10:00 am PST/ 1:00 pm EST.

October 24, 2006
NextBio's Scientific Advisory Board Brings Together Thought-leaders from Systems Biology, Genomics and Bioinformatics

Cupertino, CA, October 24, 2006 - NextBio, whose innovative knowledge-based discovery platform introduces a new paradigm in the management and interpretation of biological and clinical information, today announced the founding members of its Scientific Advisory Board (SAB): Dr. Leroy Hood, Dr. Ronald Davis, Dr. Mostafa Ronaghi, Dr. Keith Joho, Dr. Nick Tsinoremas and Dr. Saeed Tavazoie. The SAB, which comprises a broad base of scientific experts from academic and industry research settings, will offer guidance to NextBio management in ensuring the biological and clinical relevance of future product development.

Leroy Hood, M.D., Ph.D.: "One of the challenges of the new systems biology paradigm is how to enable scientists to easily sift through vast quantities of large-scale information that cannot be easily captured in published literature and, at the same time, organize and integrate different types of data in ways that are conducive to computational analysis and modeling. NextBio has made striking progress toward that objective."

Dr. Hood is President and cofounder of the Institute for Systems Biology in Seattle, Washington. He has been at the forefront of scientific discovery and technological research for more than 35 years. Dr. Hood has published more than 600 peer-reviewed papers, received 12 patents, cofounded nearly a dozen companies and was awarded the 2002 Kyoto Prize in Advanced Technology for his outstanding contributions to biotechnology and medical technology.

Ronald Davis, Ph.D.: "What NextBio is doing for biological information is analogous to what happened when we went from northern blots to microarrays."

Dr. Davis is the Director of the Stanford Genome Technology Center and Professor of Biochemistry and Genetics at the Stanford University School of Medicine. He is a world-renowned researcher in the areas of genomics and high-throughput biochemical techniques. He pioneered many of the early techniques using recombinant DNA and helped conceive of novel methods for genetic linkage analysis. Professor Davis has also been involved in the spin-off of multiple start-up companies in the area of genomics from his laboratory at Stanford.

Mostafa Ronaghi, Ph.D.: "The systematic collection of information provides the backbone of biology. Any one study is just a piece of the puzzle in an ocean of pieces. NextBio connects the pieces of the puzzle, revealing new insights into biological systems."

Dr. Ronaghi is cofounder of NextBio and an experienced entrepreneur. He cofounded Pyrosequencing in 1997 (renamed Biotage in 2003) and ParAllele BioScience in 2001 (sold to Affymetrix). He is currently a principal investigator at Stanford University focusing on developing novel tools for molecular diagnostics. Dr. Ronaghi holds more than 20 pending and issued patents and has written more than 50 peer-reviewed publications in journals and books.

Keith Joho, Ph.D.: "The research community has been looking for a solution like NextBio for the last ten years. It is going to have a huge impact on productivity."

Dr. Joho is a leader in the bioinformatics community having held senior management positions in bioinformatics at Ingenuity Systems, SurroMed, Abgenix, Roche BioScience and SUGEN. He has also served on the faculty of the Department of Biochemistry and Molecular Biology at the Louisiana State University Medical Center. He is currently a consultant focusing on informatics challenges in biopharmaceutical research.

Nick Tsinoremas, Ph.D.: "NextBio is liberating for bench scientists. It gives them an intuitive way to query across private and curated public data without having to be bioinformatics experts."

Dr. Tsinoremas is a Senior Director of Informatics at Scripps Florida where he oversees data analysis systems ranging from statistical genetics and data mining to chemo-informatics and sequence-based analysis. Previously, Dr. Tsinoremas held senior positions in computational genomics and bioinformatics at Rosetta/Merck, DoubleTwist, Incyte Genomics and Progenitor. Dr. Tsinoremas' original research includes light-regulated gene expression and circadian rhythms.

Saeed Tavazoie, Ph.D.: "NextBio's intuitive platform allows the biologist to navigate through the astronomical number of hypotheses that modern datasets make possible. This is the first step in turning mountains of data into new discoveries."

Dr. Tavazoie is a professor in the Department of Molecular Biology and the Lewis-Sigler Institute for Integrative Genomics at Princeton University. He has done pioneering research in the areas of computational biology and functional genomics. Professor Tavazoie has broad cross-disciplinary expertise in biophysics, molecular biology, genomics, computational biology and medicine. His current research is aimed at developing new conceptual frameworks for extracting biological understanding from large experimental datasets.

"NextBio's goal is to remove informatics barriers that have impeded biopharmaceutical research for years, and that goal is founded on a philosophy of innovation," said Saeid Akhtari, president, CEO and cofounder of NextBio. "This is clearly a philosophy we share with each member of our Scientific Advisory Board. We are honored to be working with this distinguished group of scientists."

October 17, 2006
NextBio Addresses Fundamental Research Challenge With General Availability of Knowledge-based Discovery Platform

October 17, 2006, Cupertino, CA - NextBio today announced the general availability of its first-of-a-kind, knowledge-based discovery platform. For nearly a year, scientists at leading research institutions have been using NextBio's platform in diverse therapeutic areas to generate new hypotheses and advance research discovery. NextBio enables scientists to make novel discoveries by leveraging information across the entire organization and across an expanding reference database of carefully curated, large-scale public studies. With an interface that's as easy to use as the most popular internet search engine, NextBio empowers any scientist to formulate complex questions across different assay platforms, data types, therapeutic areas and organisms to gain valuable scientific and clinical insights.

Among early access users are research and clinical scientists at Scripps Florida, UC Davis, Stanford University, Princeton University, Yale University, University of Florida, the Institute for Systems Biology, Genentech, and Burnham Institute, as well as other commercial and academic organizations. With NextBio, scientists can quickly associate disease states with specific pathways and genes, identify compounds with a particular mechanism of action and profile target activity across a collection of tissue signatures.

"NextBio gives researchers a view of all the different experiments in its repository at once, so they're able to come up with questions they wouldn't have thought of before", said Dr. Nick Tsinoremas, senior director of informatics at Scripps Florida. "NextBio is liberating for bench scientists because it empowers them with intuitive querying capabilities across multiple data sets without the need for bioinformatics expertise."

"With NextBio, I can accomplish in a few minutes and with just a few clicks what previously took me months to do, and that's if I could actually find all of the study results and bring them into one platform", said Dr. Frank Sharp, Professor, UC Davis M.I.N.D. Institute. "I use NextBio to narrow down my experimental hypotheses before getting into the wet lab, and again to interpret my study results in the context of the large repository of information NextBio contains."

NextBio was founded in 2004 by former executives from Silicon Genetics and ParAllele BioScience. "For years, biopharmaceutical organizations have struggled with how to develop improved therapies from knowledge buried in the vast quantities of data generated in their own research labs and available through public sources", said Saeid Akhtari, cofounder, president and CEO of NextBio. "NextBio addresses that challenge with an innovative platform that is immediately accessible to and facilitates novel insights for bench scientists, clinicians and bioinformatics experts alike."

NextBio improves the research effectiveness and efficiency of individual researchers, and automatically scales to provide productivity gains throughout the enterprise. NextBio's flexible repository integrates a wide variety of assay data types, facilitating collaboration among previously segregated research domains. Organizations can reuse and maximize the scientific value of information across projects, therapeutic areas and research silos, thereby increasing their return on investment in "omics" technologies.

The NextBio platform is offered exclusively by NextBio.